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There are 18 species belonging to the genus of Campylobacter (rRNK group I), of 
which thermophilic ones are the following: Campylobacter jejuni,  Campylobacter coli, 
Campylobacter lari and Campylobacter upsaliensis. The aim of our research was to 
determine the sensitivity of  Campylobacter species, isolated from human feces, to   
antibiotics being used in practice. The study involved 50 human strains of C. jejuni/coli 
isolated from feces in the Centre for Microbiology at the Public Health Institute Nis. 
Sensitivity was tested by applying the disk diffusion method on seven antibiotics 
(erythromycin, gentamicin, tetracycline, ciprofloxacin, hloramphenicol, cephalexin and 
nalidixic acid). Our results showed low resistance to erythromycin, gentamicin and 
tetracycline (2%), which corresponds to the studies conducted in the world. Moreover, 
these findings indicate that erythromycin may be considered as the drug of choice in the 
treatment of Campylobacter diarrhea in this region. Resistance to fluoroquinolone and   
nalidixic acid was  44%, and C. coli showed higher resistance compared to C. jejuni, 
though statistical significance was not proved. Acta Medica Medianae 2009;48(2):14-17. 
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Introduction 
 
There are 18 species belonging to the genus 
Campylobacter (rRNK group I), and among them 
the thermophilic ones are: Campylobacter jejuni, 
Campylobacter coli, Campylobacter lari and 
Campylobacter upsaliensis (1). Those bacteria 
grow best on 42 
oC (2). 
Campylobacter jejuni (C. jejuni) and Campylo-
bacter coli (C. coli) are important causes of 
diarrheal illness in all parts of the world (3). They 
are prominent cause of traveler’s diarrhea (3). In 
the United States, these infections affect 
approximately 1% of the population each year 
(4), with an estimated rate of 2.4 million cases 
per year (5). Studies conducted in England have 
s h o w n  t h a t  m o r e  t h a n  9 0 %  o f  i n f e c t i o n s  i n  
England are caused by C. jejuni, followed by 
infectious caused by C. coli. C. lari comprises less 
than 1% of the strains isolated (6). 
Campylobacteriosis is primary zoonotic 
disease, with raw and undercooked poultry being 
an important source of campylobacter infection. 
Contaminated milk, water, pork, beef, lamb and 
seafood also contribute to human infections. C. 
coli is normal inhabitant of pig’s gastrointestinal 
system (7); C. jejuni is isolated in birds (2), 
while C. upsaliensis is associated with dogs (6). 
However, the frequency and pattern of 
occurrence are different between developed and 
developing countries (especially in the number of 
cases reported in adults and the presence of any 
seasonal patterns in occurrence). In developing 
countries, most infections occur in children, while 
in developed countries campylobacteriosis predo-
minate in adults. Previously reported prevalence 
rate of Campylobacter spp. in children in Southeast 
Asia was in the range from 2.9-15% (8). 
Symptoms of campylobacteriosis usually 
seen in humans are diarrhea, fever, abdominal 
pains, cell exudates and blood in stool. However, 
illness can manifest as septicemia or myocarditis, 
pancreatitis, meningitis, holecystitis, arthritis and 
erithema nodosum. The clinical complications of 
campylobacter infections include toxic megacolon, 
hemolytic uremic syndrome, Reiter`s syndrome 
and Gullian-Barré syndrome (9). Most cases of 
campylobacter enteritis do not require antimicrobial 
treatment. It is usually short in duration, clinically 
mild and self-limited. However, some cases of 
these infections require treatment: severe and 
prolonged enteritis, septicemia and other extra 
intestinal infections (4). Also, antimicrobial treatment 
is necessary for campylobacter infections in 
immunosuppressed patients (10). 
When the therapy is necessary, drug of a 
choice is erythromycin. Tetracycline, fluoroquino-
lone, cloramphenicol, ampicillin and gentamicin are 
often used as alternative drugs for treatment (4). Acta Medica Medianae 2009,Vol.48                                      Presence of resistance in Campylobacter jejuni and Campylobacter coli 
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Within last few years, increased level of 
Campylobacter resistance to antibiotics, especially 
to erythromycin, fluoroquinolones and beta-
lactamase, has been noticed. Occurrence of resista-
nce is associated with use of macrolides and 
q u i n o l o n e s  i n  v e t e r i n a r y  m e d i c i n e  ( 5 ) .  I n  t h e  
1980, fluoroquinilones were introduced in therapy 
of enteritis caused by campylobacter, and were 
effective against most major pathogens causing 
bacterial enteritis. Fluoroquinolones initially 
showed good in vitro activity against thermophilic 
Campylobacter species. However, resistance of 
Campylobacter species toward these antibiotics 
increased, sometimes after only one or two 
treatments, whereas diarrhea caused by the 
resistant strains has longer duration (4).  
 
Aims  
 
The aim of our study was to determine the 
resistance of C. jejuni and C. coli to erythromycin, 
gentamicin, tetracycline, ciprofloxacin and chlora-
mphenicol, used in therapy as well as cephalexin 
and nalidixic acid, used for identification. 
 
Material and methods 
 
Research included 50 strains isolated and 
identified from human feces in the period   2003-
2007 at the Public Health Institute Nis. Isolation 
of thermophilic species of Campylobacter was 
conducted by culturing specimens on Skirow agar 
(bioMérieux, France) and incubated at 42
oC in 
microaerophilic atmosphere for 48 hours. For 
identification we used colony morphology (small, 
smooth, radiant, flat or convex colonies, confluent 
on the fresh media when they have a water drop 
look), microscopic examination (Gram-negative, 
curved bacilli, S-shaped), biochemical tests (oxidase 
test, catalase test, hippurate hydrolysis and auto-
matic identification system API-Campy, bioMérieux, 
France). 
Sensitivity of the strains to antibiotics was 
examined by disk-diffusion method on blood agar 
enriched with 5% of sheep blood. Suspension 
was prepared by inoculation of full loop into 5ml 
of a sterile saline and adjustment of density to 5 
McFarland standard. Disks were applied by forceps; 
distance between centers of two adjacent disks 
were 3 cm, and a distance from the edge of the 
plate was 1cm. Plates were incubated at 37
oC in 
microaerophilic conditions achieved by GasPak-
system (bioMérieux, France) within 48 hours. 
Having in mind that the size of inhibition zone 
and break-points for campylobacters are not yet 
standardized, we used recommendations for 
Staphylococcus aureus standard for erythromycin, 
and standard for Enterobacteriaceae for the rest 
of antibiotics according to Clinical Laboratory 
Standards Institute USA (CLSI), 2008. (11). We 
used disks of tetracycline (30 µg) (Bioanalyse, 
Turkey), erythromycin (15 µg), gentamicin (10 
µg), nalidixic acid (30 µg), ciprofloxacin (5 µg), 
chloramphenicol (30 µg) and cephalexin (30 µg) 
(Neo sensitabs
tm, Rosco-Diagnostica, Danmark). 
Statistical data were processed by Epi info 
software, version 5. 
 
Results  
 
Out of 50 strains, 35 C. jejuni strains and 
15 strains of C. coli were examined. Twenty-seven 
isolated strains were resistant to one antibiotic, two 
strains were resistant to two, and 19 isolates 
were resistant to three antibiotics. 
In 35 isolates of C. jejuni, 19 were 
resistant to one antibiotic (54.3%), two were 
resistant to two antibiotics (5,7%) and 12 were 
resistant to three antibiotics (34.3%). Of 15 
isolates of C. coli, eight were resistant to one 
antibiotic (53.3%), and seven were resistant to 
three antibiotics (46.7%). 
 
Table 1. Sensitivity of thermophillic Campylobacter spp. 
to examined antibiotics 
 
Sensitivity of strains 
S R  Antibiotics 
Number 
of isolates 
% 
Number 
of isolates 
% 
erythromycin 49  98  1  2 
gentamicin 49  98  1  2 
tetracycline 49  98  1  2 
ciprofloxacin  28 56 22 44 
nalidixic  acid  28 56 22 44 
chloramphenicol 48  96  2  4 
cephalexin  7  14 43 86 
S-Sensitive 
R-Resistant 
 
Table 2. Sensitivity of C. jejuni/coli to examined 
antibiotics 
 
Sensitivity of strains 
C. jejuni  C. coli 
% % 
Antibiotics 
S R S  R 
erytromycin 97,1  2,9  100  0 
gentamicin 97,1  2,9  100  0 
tetracycline 97,1  2,9  100  0 
ciprofloxacin 57,2  42,8  53,3  46,7 
nalidixic acid  57,2  42,8  53,3  46,7 
chloramphenicol 94,4  5,6  100  0 
cephalexin 20  80  0  100 
S-Sensitive 
R-Resistant 
 
Resistance to erythromycin, gentamicin and 
tetracycline was represented in low percentage 
(Table 1). Higher levels of resistance to nalidixic 
acid and ciprofloxacin were seen in C. jejuni 
(42.8%), and in C. coli (46.7%) (Table 2). There 
were not statistically significant differences 
between sensitivity to nalidixic acid and to 
ciprophloxacin within C. jejuni and C. coli strains 
(p=0.8773907; χ
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In patients up to 7 years of age (27 pts), 
resistance to ciprophloxacin was 44.4%. In 
patients from 7 to 15 years of age (7 pts), 
resistance to ciprophloxacin was 28.6%. In adult 
patients (16 pts), resistance to ciprophloxacin 
was 50%. Chi-square test showed that there was 
no statistically significant difference between inve-
stigated age groups in resistance to ciprophloxacin. 
 
Discussion 
 
Our strains showed low resistance to 
erythromycin, gentamicin and tetracycline (2%). 
Resistance data of C. jejuni and C. coli to 
erythromycin are different in different parts of a 
world. Majority of studies emphasize higher 
resistance of C. coli to erythromycin (up to 
68.4%) compared to C. jejuni (up to 11%). 
However, we did not find this in our research. 
Low and stabile resistance of thermophilic 
campylobacters to erythromycin has been found 
in Japan, Canada and Finland, while resistance is 
increasing in Sweden and Taiwan (2). Studies 
conducted in the Arab Gulf, showed a high level 
of sensitivity of isolated strains to erythromycin, 
confirming erythromycin as a drug of choice for 
enteritis caused by campylobacters (12). However, 
in Northern Ireland, mild increase of campyloba-
cter resistance to erythromycin (4.2%) in human 
population was noted (13).  
According to some studies, it seems that 
resistance to gentamicin is low. In a study 
conducted by Ge Beilei et al., which included 81 
isolates of C. jejuni and 54 isolates of C. coli 
obtained from row retail meat, resistance to 
gentamicin was not noticed (5). In the study 
conducted in Spain in the period from 1997 to 
1998, resistance of human strains to gentamicin 
was 0.4% for C. jejuni and 8.6% for C. coli (14). 
Similar studies on pediatric patients, in Spain, 
too, revealed resistance to gentamicin in 1% of 
isolated strains (15). 
Data obtained from Sweden showed that in 
the period 2000-2002 the resistance to tetra-
cycline was 4%. In other European States it was 
up to 39%, and in some Asian States up to 87% 
(16). Highest level of resistance was recorded in 
the USA for C. jejuni (85.2%), and for C. coli 
(77.8%) (5). 
Our strains showed resistance to ciprophlo-
xacin in 44%. Resistance to fluoroquinolones has 
increased from 1989 by introducing enrophlo-
xacin in veterinary as well as broad application of 
fluoroquinolones in human medicine in Europe 
(Holland, France, Spain). In regions where the 
resistance to fluoroquinolones is endemic, these 
antibiotics are not recommended in the therapy 
of diarrhea (2). In 1993, in Northern Ireland, 
resistance to fluoroquinolones was 3.8%. 
Moreover, resistance increased up to 10% until 
1995 (13). 
Our strains were resistant to nalidixic acid 
in 44%. In Northern Ireland, from 1980 to 1991, 
resistance to nalidixic acid was not detected (13). 
In the USA, detected resistance to nalidix acid 
was 1.3% in 1992 and 10.2% in 1998 (8). 
However, one study conducted in Northern Spain 
in 2005 revealed resistance up to 76% (17). 
Our strains are sensitive to chloramphe-
nicol in high percentage (98%). Many studies 
have shown high activity of chloramphenicol in 
vitro against most strains of campylobacters. 
Sagara and et al. emphasized important 
differences in sensitivity among C. jejuni and C. 
coli strains. Namely, there was no resistance in 
C. jejuni strains, while in C. coli it was recorded 
in 10% (15). In Northern Ireland, resistance to 
chloramphenicol was noticed in 1993 for the first 
time in 1.4% examined strains. In Kenya, 24% 
strains of campilobacters showed resistance to 
this drug (8). 
Our  C. jejuni strains were resistant to 
cephalexin in 80%, while C. coli strains were 100% 
resistant. Pezzotti et al. confirmed that 100% of 
human strains were resistant to first generation 
of cephalosporins (18). 
 
Conclusion 
 
Since most of our strains were sensitive to 
erythromycin, gentamicin, tetracycline, and cipro-
floxacin, besides erythromycin as a drug of choice, 
these antibiotics can be used in the therapy of 
diarrhoea caused by thermophilic campylobacters. 
However, resistance to quinolones diminishes their 
application and urges necessities of antibiotic susce-
ptibility testing, though resistance to nalidixic 
acid limits its use in identification of our strains. 
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POJAVA REZISTENCIJE KOD BAKTERIJA CAMPYLOBACTER JEJUNI I 
CAMPYLOBACTER COLI 
 
Ljiljana Ristić, Tatjana Babić, Branislava Kocić i Biljana Miljković-Selimović 
 
 
Od 18 vrsta koje pripadaju rodu Campylobacter (rRNK grupa I), termofilne su: 
Campylobacter jejuni,  Campylobacter coli,  Campylobacter lari i Campylobacter 
upsaliensis. Cilj našeg ispitivanja bio je utvrđivanje osetljivosti termofilnih vrsta 
k a m p i l o b a k t e r a  i z o l o v a n i h  i z  h u m a n o g  f e c e s a  n a  a n t i b i o t i k e  k o j i  s e  k o r i s t e  u  p r a k s i .  
Ispitivanjem je obuhvaćeno 50 humanih izolata C. jejuni/coli izolovanih u Centru za 
mikrobiologiju Instituta za javno zdravlje u Nišu. Osetljivost je testirana primenom disk 
difuzione metode na 7 antibiotika (eritromicin, gentamicin, tetraciklin, ciprofloksacin, 
hloramfenikol, cefaleksin i nalidiksična kiselina). Rezultati su pokazali nisku rezistentnost 
na eritromicin, gentamicin i tetraciklin (2%), što odgovara studijama sprovedenim u 
svetu i govori u prilog tome da se eritromicin i dalje može smatrati lekom izbora u 
lečenju dijareja izazvanih kampilobakterom na našim prostorima. Rezistentnost na 
fluorokvinolone i nalidiksičnu kiselinu iznosila je 44% pri čemu su veću rezistentnost 
pokazali izolati C. coli, u odnosu na C.jejuni, ali statistički značajna razlika nije 
dokazana. Acta Medica Medianae 2009;48(2):14-17. 
 
Ključne reči: Campylobacter jejuni, Campylobacter coli, rezistencija, disk difuzija, 
antibiotici 
 